Outlook Therapeutics, Inc. (OTLK) Tops Q2 EPS by 9c

Outlook Therapeutics, Inc. (NASDAQ: OTLK) reported Q2 EPS of ($0.89), $0.09 better than the analyst estimate of ($0.98).

For earnings history and earnings-related data on Outlook Therapeutics, Inc. (OTLK) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance